
Giuseppe Fuda

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3456503/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Amyotrophic lateral sclerosis caregiver burden and patients' quality of life during COVID-19 pandemic. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 146-148.	1.7	15
2	Tailoring patients' enrollment in ALS clinical trials: the effect of disease duration and vital capacity cutoffs. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 108-115.	1.7	1
3	Effects of intracellular calcium accumulation on proteins encoded by the major genes underlying amyotrophic lateral sclerosis. Scientific Reports, 2022, 12, 395.	3.3	7
4	Brain ¹⁸ fluorodeoxyglucose-positron emission tomography changes in amyotrophic lateral sclerosis with <i>TARDBP</i> mutations. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 1021-1023.	1.9	4
5	Validation of the Italian version of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) administered to patients and their caregivers. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 424-429.	1.7	2
6	Telemedicine for patients with amyotrophic lateral sclerosis during COVID-19 pandemic: an Italian ALS referral center experience. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 308-311.	1.7	27
7	A novel splice site FUS mutation in a familial ALS case: effects on protein expression. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, , 1-9.	1.7	2
8	Association of Variants in the <i>SPTLC1</i> Gene With Juvenile Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 1236.	9.0	46
9	G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial). BMJ Open, 2020, 10, e034049.	1.9	7
10	The transcription factor Nurr1 is up-regulated in amyotrophic lateral sclerosis patients and SOD1-G93A mice. DMM Disease Models and Mechanisms, 2020, 13, .	2.4	8
11	Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Annals of Neurology, 2019, 85, 470-481.	5.3	118
12	Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2017, 16, 208-216.	10.2	62
13	A20 in Multiple Sclerosis and Parkinson's Disease: Clue to a Common Dysregulation of Anti-Inflammatory Pathways?. Neurotoxicity Research, 2017, 32, 1-7.	2.7	23
14	Decreased Levels of Foldase and Chaperone Proteins Are Associated with an Early-Onset Amyotrophic Lateral Sclerosis. Frontiers in Molecular Neuroscience, 2017, 10, 99.	2.9	30
15	<scp>NADPH</scp> oxidase 2 (<scp>NOX</scp> 2) enzyme activation in patients with chronic inflammatory demyelinating polyneuropathy. European Journal of Neurology, 2016, 23, 958-963.	3.3	13
16	Persistent idiopathic hypoglossal nerve palsy: A motor neuron disease-mimic syndrome?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 274-276.	1.7	3
17	NADPH oxidase (NOX2) activity is a modifier of survival in ALS. Journal of Neurology, 2014, 261, 2178-2183.	3.6	36
18	UNC13A influences survival in Italian amyotrophic lateral sclerosis patients: a population-based study. Neurobiology of Aging, 2013, 34, 357.e1-357.e5.	3.1	59